|IELSG50||Pembrolizumab and radiotherapy for previously untreated patients with |
limited-stage NK/T cell lymphoma who are not eligible for chemotherapy
|Investigator responsible(s):||S. Luminari and W. Zhao|
|Objective(s):||The primary objective of the IELSG50 trial is to test the efficacy of concurrent |
RT-Pembrolizumab in patients with limited-stage high-risk NK/T cell lymphoma
who are not eligible or refuse to receive chemotherapy.